Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Arrhythmogenic Right Ventricular Cardiomyopathy: early-phase trial registry
4 of 5 indexed Arrhythmogenic Right Ventricular Cardiomyopathy trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 4 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Arrhythmogenic Right Ventricular Cardiomyopathy: 5 US clinical trials tracked, 4 recruiting.
Arrhythmogenic Right Ventricular Cardiomyopathy is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Tenaya Therapeutics, running 2 of these trials.
Enrollment posture brief
Registry condition arrhythmogenic-right-ventricular-cardiomyopathy
OPEN 4 | RECR 80% | LATE 0 | EARLY 2 | RANK #3391 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Leukemia of Ambiguous Lineage (80% recruiting · 10 trials)
Arrhythmogenic Right Ventricular Cardiomyopathy lists 4 open slots (80% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Arrhythmogenic Right Ventricular Cardiomyopathy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Arrhythmogenic Right Ventricular Cardiomyopathy is recruiting above its size-band peers.
4 of 5 indexed trials (80%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Arrhythmogenic Right Ventricular Cardiomyopathy research.
Tenaya Therapeutics accounts for 2 of 5 trials (40%). 4 distinct sponsors appear on at least one study for this condition label.
-
Typical Arrhythmogenic Right Ventricular Cardiomyopathy enrolment sits around 200 participants.
Median target enrolment is 200 among the 5 trials that report a genuine target (sentinel values excluded). 2 of those (40%) plan for fewer than 100 participants.
-
Arrhythmogenic Right Ventricular Cardiomyopathy research leans observational.
2 interventional and 3 observational studies make up this index (40% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
Mayo AVC Registry and Biobank
Mayo Clinic
NCT03049254
Pediatric Cardiomyopathy Mutation Analysis
Indiana University
NCT02432092
Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
Tenaya Therapeutics
NCT06311708
Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVC
Tenaya Therapeutics
NCT06228924
Pilot Randomized Trial With Flecainide in ARVC Patients
University of Rochester
NCT03685149
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Arrhythmogenic Right Ventricular Cardiomyopathy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Arrhythmogenic Right Ventricular Cardiomyopathy trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Arrhythmogenic Right Ventricular Cardiomyopathy page
5 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Arrhythmogenic Right Ventricular Cardiomyopathy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Tenaya Therapeutics sponsors the most Arrhythmogenic Right Ventricular Cardiomyopathy trials on record, review their full trial history before evaluating a specific study. See Tenaya Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Arrhythmogenic Right Ventricular Cardiomyopathy condition card totals 5 registered trials; most-linked intervention Flecainide Pill; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.